Today's Challenges. Tomorrow's Solutions.

Strategic Solutions for Dermatology That Turn Clinical Volume Into Enterprise Value

Dermatology runs on high-volume medical visits, in-house dermatopathology and Mohs surgery, and a cosmetic cash-pay line that moves on entirely different economics. Fulcrum Health Partners advises dermatology groups, pathology and Mohs practices, and PE-backed platforms across commercial rate strategy, path and Mohs margin protection, modifier-25 and downcoding defense, and biologics access — converting demand into durable, defensible margin.

Model Your Reimbursement Opportunity → Speak with a Dermatology Advisor

$2.7B

Reimbursement Opportunity Identified

12,500+

Payer Contracts Reviewed

States Served

350+

Client Engagements

Automatic inflation update in the Medicare fee schedule

>3x

Revenue per Mohs case vs. a standard office visit

The modifier under heaviest payer scrutiny on E/M-with-procedure claims

1 in 3

Dermatology practices now aligned with a PE-backed platform

The Dermatology Reimbursement Landscape

Four revenue engines, four sets of economics, one contract strategy.

A dermatology enterprise is really four businesses stacked in one clinic — and each one is priced, coded, and contracted differently.

Medical dermatology generates enormous claim volume through E/M visits, biopsies, and destructions — but its margin is quietly compressed by payer downcoding and relentless modifier-25 scrutiny when an E/M service is billed alongside a same-day procedure. In-house dermatopathology and Mohs micrographic surgery are the true margin centers, where global-versus-technical/professional billing, self-referral and Stark structure, and commercial rate positioning determine whether the ancillary is an asset or an exposure.

Running parallel is a cosmetic and aesthetic cash-pay line — priced outside insurance and skewing the payer mix toward commercial — plus a biologics book for psoriasis and atopic dermatitis burdened by prior authorization, step therapy, and the buy-and-bill versus specialty-pharmacy decision. Meanwhile dermatology has become one of the most heavily private-equity-consolidated specialties, where MSO platform economics reward de novo and add-on growth. The same visit, biopsy, or excision can be worth dramatically different amounts depending on how it is coded, contracted, and structured — and that is precisely where Fulcrum works.

Illustrative composition. Replace with your confirmed figures before launch; reflects current CMS/MedPAC methodology and public payer data, 2024–2026.

Net Revenue Composition — Illustrative

Where a dermatology enterprise earns its margin

Medical E/M & procedures

Dermatopathology

Mohs surgery

Cosmetic cash-pay

The visit drives volume; path and Mohs drive margin. Fulcrum quantifies each line — coded, contracted, and structured.

Our Dermatology Advisory Solutions

Advisory organized around the economics you manage

Not a service menu — the reimbursement problems that decide dermatology margin and enterprise value, and the strategy, analytics, and negotiation capabilities that resolve them.

01 The Challenge — You can't negotiate what you haven't benchmarked

Contract Assessment & Reimbursement Benchmarking

We digitize and normalize every payer contract and fee schedule, then benchmark your medical dermatology, dermatopathology, and Mohs reimbursement against Medicare and against market — quantifying exactly where you sit, line by line, and what the opportunity is worth.

Contract digitization

Fee schedule normalization

% of Medicare benchmarking

Path & Mohs code-level analysis

Geographic market comparison

EOB & payment variance analysis

Underpayment identification

Revenue opportunity quantification

Contract performance scoring

02 The Challenge — Little leverage one contract at a time

Managed Care Negotiations & Strategy

We build the positioning, data, and negotiation strategy to improve commercial rates across medical, pathology, and Mohs schedules — from renewals and redlining to executive payer meetings, informed by your cosmetic and specialty mix.

Commercial rate improvement

Contract renewals & redlining

Path & Mohs schedule strategy

MA & Medicaid managed care

Escalation & executive strategy

Network participation strategy

03 The Challenge — Decisions made without modeling the downside

Contract Modeling & Analytics

CPT- and payer-level modeling that turns claims and contracts into scenario analysis and side-by-side comparisons — including the economics of bringing pathology in-house or adding a Mohs surgeon.

CPT-level reimbursement modeling

Scenario & what-if analysis

Payer mix & revenue forecasting

In-house vs. outside path modeling

Mohs & ancillary ROI

Executive Power BI dashboards

04 The Challenge — Negotiating blind to what competitors are paid

Payer Transparency & Market Rate Intelligence

Federal Transparency in Coverage data has transformed the negotiating table. We mine machine-readable rate files to show what competing dermatology and pathology groups are actually paid — and arm your team with it.

Transparency in Coverage analysis

Competitor rate benchmarking

Market rate positioning

Negotiation preparation

Peer comparison

Commercial opportunity sizing

05 The Challenge — Contract terms that aren't honored

Payer / Provider Disputes & Enforcement

When payers downcode E/M billed with procedures, deny modifier-25, or reprice pathology and Mohs claims, we lead the interpretation, escalation, and enforcement — turning contractual entitlement into collected revenue.

Contract interpretation

Modifier-25 & downcoding challenges

Payment & claims disputes

Path & Mohs repricing appeals

Escalation support

Contract enforcement

06 The Challenge — Earned revenue that never arrives

Underpayment Recovery & Revenue Integrity

Our analytics compare contracts, fee schedules, allowables, and EOB/remittance data to detect variances, quantify recoverable revenue, and fix the root cause — with particular focus on high-value pathology, Mohs, and biologics claims.

Contract compliance auditing

Underpayment & variance detection

Automated EOB/remit analytics

Buy-and-bill drug reimbursement

Recovery & appeals strategy

Revenue integrity programs

07 The Challenge — Where the market and the platform economics are moving

Covered Lives & Market Intelligence

We map covered lives, payer penetration, and competitive density across your market so you prioritize the negotiations, de novo sites, and add-on targets that move the most margin — critical intelligence for a PE-backed platform strategy.

Covered-lives analysis

Payer penetration & market share

De novo & add-on site screening

Network adequacy leverage

MSO platform benchmarking

Commercial opportunity identification

Reimbursement Intelligence in Action

Your practice economics, by dermatology profile

Fulcrum turns your claims, pathology, and contract data into executive dashboards. Select a profile to explore a sample payer mix and revenue view spanning insured medical, path, and Mohs alongside the cosmetic cash-pay line.

Independent Medical Dermatology · Payer Mix & Revenue Live Sample

Payer Mix (by patient volume)

Net Revenue by Payer — Insured vs. Cosmetic Cash-Pay

Insured medical, path & MohsCosmetic / aesthetic cash-pay

Illustrative sample dashboard. Fulcrum builds these from your practice-management, claims, pathology, and contract data by CPT, payer, and contract.

The Forces Reshaping Dermatology Economics

The strategic questions every dermatology leader now faces

Beyond the fee schedule, these are the dynamics that decide dermatology margin — and where Fulcrum builds the strategy.

PE Consolidation & MSO Platform Economics

Competing with — and evaluating alignment against — the PE-backed platforms consolidating dermatology through de novo builds and add-on acquisitions, where contract quality drives valuation.

Dermatopathology & Self-Referral Structure

Capturing in-house pathology margin while navigating Stark self-referral limits and the global versus technical/professional billing split that determines what you actually collect.

Modifier-25 & E/M Downcoding

Defending payment when an E/M service is billed with a same-day procedure, as payers intensify modifier-25 edits, downcoding, and post-payment review.

Biologics: Prior Auth, Step Therapy & Buy-and-Bill

Managing access and reimbursement for psoriasis and atopic dermatitis biologics amid step therapy, prior authorization, and the buy-and-bill versus specialty-pharmacy decision.

The Declining Conversion Factor

Absorbing annual real-terms cuts to Medicare physician payment with no automatic inflation update — a direct hit to high-volume medical dermatology.

The Cosmetic Cash-Pay Line & Payer Mix

Running an aesthetic cash-pay business in parallel with insured care, protecting a commercial-skewed payer mix, and pricing services outside the fee schedule.

Dermatology Reimbursement Calculator

See what optimized commercial reimbursement is worth

Model the annual uplift from moving your commercial rates toward market and optimized levels — expressed as a percentage of Medicare — across your medical, dermatopathology, and Mohs book. Cosmetic cash-pay is priced outside insurance and excluded.

Your inputs

Enter approximate figures — nothing is stored or transmitted.

Annual commercial reimbursement — medical, path & Mohs

Current commercial rate (% of Medicare)

Optimized commercial rate (% of Medicare) — 135%

Estimated annual reimbursement uplift

Adjust the inputs to model your opportunity.

Per $1M of commercial revenue

3-year cumulative

Directional estimate for discussion only. Models commercial rate improvement across the medical, dermatopathology, and Mohs book; recovering underbilled pathology and Mohs capture is additive, and cosmetic cash-pay is excluded. A Fulcrum analysis models your actual contracts and payer mix.

Why Dermatology Leaders Choose Fulcrum

The advisor that speaks dermatology's economic language

Independent by design and fluent in the economics of the specialty — medical E/M and procedures, dermatopathology and Mohs margin, biologics access, the cosmetic cash-pay line, and PE platform value — delivered by the people who do the work.

Independent Advisor

No networks, no downstream fees — only your economics.

Dermatology Fluency

Fluent in the medical, path, Mohs, and cosmetic mix.

Commercial Rate Benchmarking

Market and transparency data behind every ask.

Path, Mohs & CPT Analytics

Modeling down to the code and the ancillary line.

National Payer Experience

Insight into payer policy in every market.

Modifier-25 & Downcoding Defense

Protecting E/M-with-procedure payment.

Negotiation Leadership

Senior advisors at the table, not junior staff.

PE & Transaction Insight

Contract diligence and value creation for platforms.

Client Outcomes

How Fulcrum helps — and what it's worth

Anonymized outcomes from Fulcrum engagements with dermatology groups, pathology and Mohs practices, and platforms.

Independent Medical Dermatology

17%

commercial rate improvement

Situation: benchmarking exposed medical and biopsy rates well below market with two dominant commercial payers. Result: we repositioned the group and renegotiated both contracts, lifting blended commercial reimbursement without adding a single visit.

Derm + Dermatopathology Group

$3.8M

pathology & Mohs revenue recovered

Situation: outside-lab pathology and repriced Mohs claims were leaking value across a multisite group. Result: we modeled bringing pathology in-house within Stark limits, corrected the global-vs-technical billing split, and recovered systematic underpayments.

PE-Backed Derm Platform

8 pts

margin from contract harmonization

Situation: a multi-state platform inherited a patchwork of legacy contracts through rapid add-on acquisition. Result: we harmonized rates to the best-in-class schedule and standardized modifier-25 defense — lifting EBITDA ahead of a recapitalization.

Fulcrum Intelligence

Dermatology insights & analysis

Executive briefings on the forces moving dermatology economics — the fee schedule, dermatopathology and Mohs margin, modifier-25 scrutiny, biologics access, and PE consolidation.

Protecting Modifier-25 & E/M-With-Procedure Payment → The Economics of In-House Dermatopathology & Mohs →

Explore Dermatology Insights →